{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.55","value":"1.76"},{"groupId":"OG001","spread":"1.31","value":"1.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Baseline; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.98","value":"-0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C1D1; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.34","value":"0.26"},{"groupId":"OG001","spread":"0.84","value":"-0.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C1D8; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.31","value":"0.00"},{"groupId":"OG001","spread":"0.93","value":"-0.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Change at C1D15; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.30","value":"-0.23"},{"groupId":"OG001","spread":"0.91","value":"-0.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at C2D1; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.59","value":"0.17"},{"groupId":"OG001","spread":"0.91","value":"-0.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C2D8; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.53","value":"-0.13"},{"groupId":"OG001","spread":"0.90","value":"-0.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Change at C2D15; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.60","value":"-0.26"},{"groupId":"OG001","spread":"1.13","value":"-0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C3D1; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.63","value":"-0.13"},{"groupId":"OG001","spread":"1.20","value":"-0.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Change at C3D8; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.52","value":"-0.42"},{"groupId":"OG001","spread":"1.05","value":"-0.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Change at C3D15; Mean core symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"1.60"},{"groupId":"OG001","spread":"1.11","value":"1.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Baseline; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.96","value":"-0.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C1D1; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.40","value":"-0.22"},{"groupId":"OG001","spread":"0.96","value":"-0.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C1D8; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"-0.43"},{"groupId":"OG001","spread":"1.13","value":"-0.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Change at C1D15; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"-0.49"},{"groupId":"OG001","spread":"0.92","value":"-0.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at C2D1; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.63","value":"-0.46"},{"groupId":"OG001","spread":"0.87","value":"-0.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at C2D8; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.47","value":"-0.69"},{"groupId":"OG001","spread":"0.93","value":"-0.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at C2D15; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.48","value":"-0.65"},{"groupId":"OG001","spread":"0.97","value":"-0.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at C3D1; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.58","value":"-0.51"},{"groupId":"OG001","spread":"0.97","value":"-0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Change at C3D8; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"-0.83"},{"groupId":"OG001","spread":"0.97","value":"-0.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Change at C3D15; Mean module symptom severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.05","value":"1.81"},{"groupId":"OG001","spread":"2.25","value":"1.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Baseline; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"1.49","value":"-0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at C1D1; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.78","value":"0.45"},{"groupId":"OG001","spread":"2.14","value":"-0.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Change at C1D8; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.85","value":"0.36"},{"groupId":"OG001","spread":"2.04","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Change at C1D15; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.73","value":"0.01"},{"groupId":"OG001","spread":"1.78","value":"-0.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Change at C2D1; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.20","value":"0.58"},{"groupId":"OG001","spread":"1.81","value":"-0.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at C2D8; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.84","value":"0.06"},{"groupId":"OG001","spread":"1.59","value":"-0.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at C2D15; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.02","value":"-0.02"},{"groupId":"OG001","spread":"2.06","value":"-0.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at C3D1; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.91","value":"0.15"},{"groupId":"OG001","spread":"2.09","value":"-0.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Change at C3D8; Mean interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.01","value":"-0.07"},{"groupId":"OG001","spread":"2.18","value":"-0.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Change at C3D15; Mean interference"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"MEAN","populationDescription":"Patient reported outcomes (PRO) evaluable population included all participants with baseline and at least one post-baseline PRO assessment. Here, 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure and 'Number Analyzed' = participants evaluable at specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Days 1, 8, and 15 of Cycles 1, 2, and 3; Cycle length = 28 days","title":"Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}